A Phase 2 interventional study of SR604 in Von Willebrand Disease (VWD), sponsored by Shanghai RAAS Blood Products Co., Ltd.. Recruiting at 9 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by Shanghai RAAS Blood Products Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in patients with von Willebrand disease.
96 studies on the registry are indexed under von Willebrand Diseases; 25 are open to participants now.
This study's planned enrollment of 24 is close to the median of 25 across 41 interventional studies indexed under von Willebrand Diseases.
Browse von Willebrand Diseases studies →Shanghai RAAS Blood Products Co., Ltd. is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must meet ALL of the following inclusion criteria to be enrolled:
Exclusion Criteria:
Patients meeting ANY of the following exclusion criteria will not be enrolled:
Meeting any of the following criteria at screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with Von Willebrand Disease will receive SR604 dose 1 as multiple SC injections every 4-weeks, or dose 2 as multiple SC injections every 4-weeks/6-weeks/8-weeks.
Drug: SR604
SR604 will be administered as SC injection.
Total annualized bleeding rate (ABR) after treatment
Time frame: From baseline, through study completion, an average of 52 weeks
Annualized spontaneous bleeding rate
Time frame: From baseline, through study completion, an average of 52 weeks
Annualized traumatic bleeding rate
Time frame: From baseline, through study completion, an average of 52 weeks
Overall annualized bleeding rate, annualized spontaneous bleeding rate, and annualized traumatic bleeding rate
Time frame: From baseline, through study completion, an average of 52 weeks
EQ-5D-5L health questionnaire utility value
Time frame: From baseline, through study completion, an average of 52 weeks
Change in EQ-VAS score from baseline
Time frame: From baseline, through study completion, an average of 52 weeks
PK parameters after first dose:Peak Plasma Concentration (Cmax)
Time frame: Day1
Pharmacokinetic parameters after multiple doses: Peak Plasma Concentration (Cmax)
Time frame: From baseline, through study completion, an average of 52 weeks
Incidence of Adverse Events (AEs)
Number of participants experiencing at least one AE
Time frame: From baseline, through study completion, an average of 52 weeks
PK parameters after first dose:Time to Peak Plasma Concentration (Tmax)
Time frame: Day1
Safety: Number and incidence of patients with anti-drug antibodies (ADA)
Time frame: From baseline, through study completion, an average of 52 weeks
Pharmacokinetic parameters after multiple doses: Time to Peak Plasma Concentration (Tmax)
Time frame: From baseline, through study completion, an average of 52 weeks
Incidence of Serious Adverse Events (SAEs)
Number of participants experiencing at least one SAE
Time frame: From baseline, through study completion, an average of 52 weeks
Incidence of Adverse Events of Special Interest (AESIs)
Number of participants experiencing at least one AESI
Time frame: From baseline, through study completion, an average of 52 weeks
Pharmacodynamic indicators:protein C
Time frame: From baseline, through study completion, an average of 52 weeks
Pharmacodynamic indicators:prothrombin time (PT)
Time frame: From baseline, through study completion, an average of 52 weeks
Pharmacokinetic parameters after multiple doses:Time to Peak Plasma Concentration (Tmax)
Time frame: From baseline, through study completion, an average of 52 weeks
Pharmacokinetic parameters after multiple doses: Area Under the Concentration-Time Curve from Zero to Last Quantifiable Time Point (AUC0-t)
Time frame: From baseline, through study completion, an average of 52 weeks
Pharmacodynamic indicators:Protac-APTT (Protac-induced protein C-activated APTT assay)
Time frame: From baseline, through study completion, an average of 52 weeks
Change from baseline in PBAC score at Week 24 of treatment and over the total treatment period (including treatment period and extended treatment period) (females with menstruation only);
Time frame: From baseline, through study completion, an average of 52 weeks
Annualized menorrhagia bleeding rate at Week 24 of treatment and over the total treatment period (including treatment period and extended treatment period) (females with menstruation only);
Time frame: From baseline, through study completion, an average of 52 weeks
Categorization of replacement therapeutic agents prior to investigational product administration, at Week 24 of treatment, and over the total treatment period (including treatment period and extended treatment period).
Time frame: From baseline, through study completion, an average of 52 weeks
Started Nov 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SR604
Shanghai RAAS Blood Products Co., Ltd. →